Search tips
Search criteria 


Logo of jnciLink to Publisher's site
J Natl Cancer Inst. 2010 March 17; 102(6): 365–367.
Published online 2010 March 17. doi:  10.1093/jnci/djq031
PMCID: PMC2841039

Lifestyle Factors and Microsatellite Instability in Colorectal Cancer: The Evolving Field of Molecular Pathological Epidemiology

Colorectal cancer is not a single disease. It encompasses heterogeneous diseases with different sets of genetic and epigenetic alterations. Each tumor arises and behaves in a unique fashion that is unlikely to be exactly recapitulated by any other tumor (1). Nevertheless, we classify colorectal cancers into a limited number of groups (eg, microsatellite instability [MSI]-high vs microsatellite stability [MSS]) because we assume that tumors with similar characteristics have arisen through common mechanisms and behave in a similar fashion (1).

Traditional epidemiology research has typically investigated factors that are associated with the overall risk of colorectal cancer, although distinct risk factors have long been recognized for colon and rectal cancers. Traditional pathology research has explored histopathologic and molecular characteristics to predict prognosis and response to specific treatment (2). More recently, these two approaches have converged to improve our understanding of how particular exposures influence carcinogenesis by examining molecular pathological marks of tumor initiation or progression, in relation to exposures of interest, for both etiology (327) and prognosis (2834). These new research efforts can be thought of as molecular pathological epidemiology, a multidisciplinary investigation of the interrelationships between exogenous and endogenous (eg, germline genetic) factors, tumor molecular signatures, and tumor initiation, progression, and response to treatment.

In this issue of Journal, Campbell et al. (35) describe a case–control study of body mass index (BMI) and colorectal cancer risk in relation to tumor MSI status. As others have found (36,37), the authors showed that prediagnosis BMI was associated with an increased risk of colorectal cancer. In addition, they showed that this excess risk was limited to MSS tumors (for a BMI increment of 5 kg/m2, adjusted odds ratio = 1.38, 95% confidence interval = 1.24 to 1.54); BMI was not associated with the risk of MSI-high tumors (adjusted odds ratio = 1.05; 95% confidence interval = 0.84 to 1.31).

Two previous case–control studies have examined the relationship between BMI and colon cancer risk by MSI status (5,10). Slattery et al. (5) examined 118 MSI-high and 696 MSS tumors and found that high BMI was associated with the risk of MSS tumors but not with the risk of MSI-high tumors among men; they observed no such difference in women. Satia et al. (10) examined 49 MSI-high and 437 MSI-low or MSS tumors and found that high BMI before diagnosis was associated with the risk of MSI-low or MSS tumors but not with the risk of MSI-high tumors. These results are generally consistent with those of Campbell et al. (35), providing further evidence for the specific relationship between obesity and the risk of MSS cancer. The specificity of this link not only reinforces a causal interpretation but also points the way to a specific mechanism.

Experimental evidence supports the link between obesity and gastrointestinal tumorigenesis in Apc-mutant mice (38). In human colorectal cancer, APC mutations and WNT/CTNNB1 (β-catenin) activation are inversely associated with the CpG island methylator phenotype (CIMP) (39,40), which is strongly associated with MSI (4144). CIMP is the most common cause of MSI, which occurs through epigenetic inactivation of a mismatch repair gene MLH1 (43,44). CIMP status and MSI status are major determinants of epigenomic and genomic characteristics (1) and are associated with many specific molecular events (1,43,44). For example, tumor expression of fatty acid synthase (FASN) is positively associated with MSI (45,46). FASN is inhibited by AMP-activated protein kinase (47,48), which is activated by a deficiency of cellular energy source ATP. Obesity is associated with reduced survival among colon cancer patients (49,50), and this association appears to be limited to patients with FASN-expressing tumors (28). Thus, obesity likely interacts with FASN in colorectal cancer cells to modify tumor behavior (28). The differential influence of obesity with respect to MSI vs MSS colorectal cancer incidence suggested by Campbell et al. (35) could potentially be explained by FASN. Alternatively, MSI status might serve as a surrogate for CIMP status or other molecular changes in colorectal cancer. Further studies are necessary to resolve this issue.

The results of Campbell et al. suggest that the increased risk of colorectal cancer associated with obesity is restricted to MSS tumors. Along with the findings by other investigators (327), these molecular pathological epidemiology data imply that molecular markers (such as MSI) can be used to classify colorectal cancers into distinct subtypes, which have implications for both etiology and prevention.

Molecular pathological epidemiology is a promising approach to investigate molecular mechanisms of carcinogenesis. Nonetheless, it faces all of the challenges inherent in epidemiological and pathology research as well as some unique limitations. For example, analyses are limited to case subjects for whom tumor tissue specimens are available. Thus, the size of any given sample in a molecular pathological epidemiology study will always be smaller than that of the parent study. Differential tissue availability can be a source of selection bias. The potential for bias will vary by many factors that may affect availability of tissue. Molecular pathological epidemiology, by definition, is based on subset analyses by tumor subtype, which further limits the sample size. Therefore, for adequate statistical power, large sample sizes are necessary. Also, the subset analyses exacerbate the potential for false-positive findings because of multiple hypothesis testing. If one crosses a wide range of lifestyle and other factors with a variety of molecularly defined tumor types, the likelihood for a nominally statistically significant chance finding is high. Thus, lack of clearly defined a priori causal hypotheses can be another caveat that may be more problematic in molecular pathological epidemiology than in traditional epidemiology. Such prior hypotheses could be based on earlier exploratory findings (35) or on the underlying biology. For example, it would be reasonable to consider a causal relation between one-carbon nutrients and genetic and epigenetic alterations (58,11,1723,27) because one-carbon reactions are essential for both DNA methylation and synthesis. However, the relationship between obesity (and associated metabolic conditions) and tumor MSI status appears to be indirect. Often, findings on molecular subtypes are exploratory, and the data should be interpreted with caution. Hypotheses generated by epidemiological research with multiple hypothesis testing should be validated in independent datasets.

In summary, the article by Campbell et al. (35) represents a prototypical study in the evolving field of molecular pathological epidemiology. This approach will continue to provide useful insights on carcinogenic processes and help us improve cancer prevention and therapeutic strategies.


Supported in part by US National Institute of Health grants P01 CA87969, P01 CA55075 and K07 CA122826 (to S.O.).


The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute or National Institute of Health. The funders had no role in preparation of the manuscript. No conflicts of interest exist.


1. Ogino S, Goel A. Molecular classification and correlates in colorectal cancer. J Mol Diagn. 2008;10(1):13–27. [PubMed]
2. Hamilton SR. Targeted therapy of cancer: new roles for pathologists in colorectal cancer. Mod Pathol. 2008;21(suppl 2):S23–S30. [PubMed]
3. Martinez ME, Maltzman T, Marshall JR, et al. Risk factors for Ki-ras protooncogene mutation in sporadic colorectal adenomas. Cancer Res. 1999;59(20):5181–5185. [PubMed]
4. Slattery ML, Curtin K, Anderson K, et al. Associations between dietary intake and Ki-ras mutations in colon tumors: a population-based study. Cancer Res. 2000;60(24):6935–6941. [PubMed]
5. Slattery ML, Curtin K, Anderson K, et al. Associations between cigarette smoking, lifestyle factors, and microsatellite instability in colon tumors. J Natl Cancer Inst. 2000;92(22):1831–1836. [PubMed]
6. Slattery ML, Anderson K, Curtin K, et al. Lifestyle factors and Ki-ras mutations in colon cancer tumors. Mutat Res. 2001;483(1–2):73–81. [PubMed]
7. Diergaarde B, Braam H, van Muijen GN, Ligtenberg MJ, Kok FJ, Kampman E. Dietary factors and microsatellite instability in sporadic colon carcinomas. Cancer Epidemiol Biomarkers Prev. 2003;12(11, pt 1):1130–1136. [PubMed]
8. English DR, Young JP, Simpson JA, et al. Ethnicity and risk for colorectal cancers showing somatic BRAF V600E mutation or CpG island methylator phenotype. Cancer Epidemiol Biomarkers Prev. 2008;17(7):1774–1780. [PubMed]
9. Newcomb PA, Zheng Y, Chia VM, et al. Estrogen plus progestin use, microsatellite instability, and the risk of colorectal cancer in women. Cancer Res. 2007;67(15):7534–7539. [PubMed]
10. Satia JA, Keku T, Galanko JA, et al. Diet, lifestyle, and genomic instability in the North Carolina Colon Cancer Study. Cancer Epidemiol Biomarkers Prev. 2005;14(2):429–436. [PubMed]
11. Brink M, Weijenberg MP, de Goeij AF, et al. Dietary folate intake and k-ras mutations in sporadic colon and rectal cancer in The Netherlands Cohort Study. Int J Cancer. 2005;114(5):824–830. [PubMed]
12. Chia VM, Newcomb PA, Bigler J, Morimoto LM, Thibodeau SN, Potter JD. Risk of microsatellite-unstable colorectal cancer is associated jointly with smoking and nonsteroidal anti-inflammatory drug use. Cancer Res. 2006;66(13):6877–6883. [PubMed]
13. de Vogel S, van Engeland M, Luchtenborg M, et al. Dietary folate and APC mutations in sporadic colorectal cancer. J Nutr. 2006;136(12):3015–3021. [PubMed]
14. Samowitz WS, Albertsen H, Sweeney C, et al. Association of smoking, CpG island methylator phenotype, and V600E BRAF mutations in colon cancer. J Natl Cancer Inst. 2006;98(23):1731–1738. [PubMed]
15. Weijenberg MP, Luchtenborg M, de Goeij AF, et al. Dietary fat and risk of colon and rectal cancer with aberrant MLH1 expression, APC or KRAS genes. Cancer Causes Control. 2007;18(8):865–879. [PMC free article] [PubMed]
16. Chan AT, Ogino S, Fuchs CS. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med. 2007;356(21):2131–2142. [PubMed]
17. Slattery ML, Curtin K, Sweeney C, et al. Diet and lifestyle factor associations with CpG island methylator phenotype and BRAF mutations in colon cancer. Int J Cancer. 2007;120(3):656–663. [PubMed]
18. van den Donk M, Pellis L, Crott JW, et al. Folic acid and vitamin B-12 supplementation does not favorably influence uracil incorporation and promoter methylation in rectal mucosa DNA of subjects with previous colorectal adenomas. J Nutr. 2007;137(9):2114–2120. [PubMed]
19. Schernhammer ES, Ogino S, Fuchs CS. Folate intake and risk of colon cancer in relation to p53 status. Gastroenterology. 2008;135(3):770–780. [PMC free article] [PubMed]
20. Schernhammer ES, Giovannuccci E, Fuchs CS, Ogino S. A prospective study of dietary folate and vitamin B and colon cancer according to microsatellite instability and KRAS mutational status. Cancer Epidemiol Biomarkers Prev. 2008;17(10):2895–2898. [PMC free article] [PubMed]
21. Campbell PT, Curtin K, Ulrich CM, et al. Mismatch repair polymorphisms and risk of colon cancer, tumour microsatellite instability and interactions with lifestyle factors. Gut. 2009;58(5):661–667. [PMC free article] [PubMed]
22. Poynter JN, Haile RW, Siegmund KD, et al. Associations between smoking, alcohol consumption, and colorectal cancer, overall and by tumor microsatellite instability status. Cancer Epidemiol Biomarkers Prev. 2009;18(10):2745–2750. [PMC free article] [PubMed]
23. Van Guelpen B, Dahlin AM, Hultdin J, et al. One-carbon metabolism and CpG island methylator phenotype status in incident colorectal cancer: a nested case-referent study. Cancer Causes Control. 2009 In press. [PubMed]
24. Hughes LA, van den Brandt PA, de Bruine AP, et al. Early life exposure to famine and colorectal cancer risk: a role for epigenetic mechanisms. PLoS One. 2009;4(11) e7951. [PMC free article] [PubMed]
25. Lindor NM, Yang P, Evans I, et al. Alpha-1-antitrypsin deficiency and smoking as risk factors for mismatch repair deficient colorectal cancer: a study from the colon cancer family registry. Mol Genet Metab. 2010;99(2):157–159. [PMC free article] [PubMed]
26. Curtin K, Samowitz WS, Wolff RK, Herrick J, Caan BJ, Slattery ML. Somatic alterations, metabolizing genes and smoking in rectal cancer. Int J Cancer. 2009;125(1):158–164. [PMC free article] [PubMed]
27. Schernhammer ES, Giovannucci E, Kawasaki T, Rosner B, Fuchs CS, Ogino S. Dietary folate, alcohol, and B vitamins in relation to LINE-1 hypomethylation in colon cancer. Gut. 2010 In press. doi:10.1136/gut.2009.183707. [PMC free article] [PubMed]
28. Ogino S, Nosho K, Meyerhardt JA, et al. Cohort study of fatty acid synthase expression and patient survival in colon cancer. J Clin Oncol. 2008;26(35):5713–5720. [PMC free article] [PubMed]
29. Chan AT, Ogino S, Fuchs CS. Aspirin use and survival after diagnosis of colorectal cancer. JAMA. 2009;302(6):649–658. [PMC free article] [PubMed]
30. Ogino S, Nosho K, Baba Y, et al. A cohort study of STMN1 expression in colorectal cancer: body mass index and prognosis. Am J Gastroenterol. 2009;104(8):2047–2056. [PMC free article] [PubMed]
31. Ogino S, Nosho K, Shima K, et al. p21 expression in colon cancer and modifying effects of patient age and body mass index on prognosis. Cancer Epidemiol Biomarkers Prev. 2009;18(9):2513–2521. [PMC free article] [PubMed]
32. Ogino S, Shima K, Nosho K, et al. A cohort study of p27 localization in colon cancer, body mass index, and patient survival. Cancer Epidemiol Biomarkers Prev. 2009;18(6):1849–1858. [PMC free article] [PubMed]
33. Baba Y, Nosho K, Shima K, et al. Relationship of CDX2 loss with molecular features and prognosis in colorectal cancer. Clin Cancer Res. 2009;15(14):4665–4673. [PMC free article] [PubMed]
34. Meyerhardt JA, Ogino S, Kirkner GJ, et al. Interaction of molecular markers and physical activity on mortality in patients with colon cancer. Clin Cancer Res. 2009;15(18):5931–5936. [PMC free article] [PubMed]
35. Campbell PT, Jacobs ET, Ulrich CM, et al. Case—control study of overweight, obesity, and colorectal cancer, overall and by tumor microsatellite instability status. J Natl Cancer Inst. 2010;102(6):391–400. [PMC free article] [PubMed]
36. Giovannucci E, Ascherio A, Rimm EB, Colditz GA, Stampfer MJ, Willett WC. Physical activity, obesity, and risk for colon cancer and adenoma in men. Ann Intern Med. 1995;122(5):327–334. [PubMed]
37. Caan BJ, Coates AO, Slattery ML, Potter JD, Quesenberry CP, Jr, Edwards SM. Body size and the risk of colon cancer in a large case-control study. Int J Obes Relat Metab Disord. 1998;22(2):178–184. [PubMed]
38. Gravaghi C, Bo J, Laperle KM, et al. Obesity enhances gastrointestinal tumorigenesis in Apc-mutant mice. Int J Obes (Lond) 2008;32(11):1716–1719. [PubMed]
39. Samowitz WS, Slattery ML, Sweeney C, Herrick J, Wolff RK, Albertsen H. APC mutations and other genetic and epigenetic changes in colon cancer. Mol Cancer Res. 2007;5(2):165–170. [PubMed]
40. Kawasaki T, Nosho K, Ohnishi M, et al. Correlation of beta-catenin localization with cyclooxygenase-2 expression and CpG island methylator phenotype (CIMP) in colorectal cancer. Neoplasia. 2007;9(7):569–577. [PMC free article] [PubMed]
41. Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A. 1999;96(15):8681–8686. [PubMed]
42. Weisenberger DJ, Siegmund KD, Campan M, et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet. 2006;38(7):787–793. [PubMed]
43. Nosho K, Irahara N, Shima K, et al. Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample. PLoS One. 2008;3(11) e3698. [PMC free article] [PubMed]
44. Samowitz W, Albertsen H, Herrick J, et al. Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer. Gastroenterology. 2005;129(3):837–845. [PubMed]
45. Ogino S, Kawasaki T, Ogawa A, Kirkner GJ, Loda M, Fuchs CS. Fatty acid synthase overexpression in colorectal cancer is associated with microsatellite instability, independent of CpG island methylator phenotype. Hum Pathol. 2007;38(6):842–849. [PubMed]
46. Uddin S, Hussain AR, Ahmed M, et al. High prevalence of fatty acid synthase expression in colorectal cancers in Middle Eastern patients and its potential role as a therapeutic target. Am J Gastroenterol. 2009;104(7):1790–1801. [PubMed]
47. An Z, Wang H, Song P, Zhang M, Geng X, Zou MH. Nicotine-induced activation of AMP-activated protein kinase inhibits fatty acid synthase in 3T3L1 adipocytes: a role for oxidant stress. J Biol Chem. 2007;282(37):26793–26801. [PubMed]
48. Foretz M, Carling D, Guichard C, Ferre P, Foufelle F. AMP-activated protein kinase inhibits the glucose-activated expression of fatty acid synthase gene in rat hepatocytes. J Biol Chem. 1998;273(24):14767–14771. [PubMed]
49. Haydon AM, Macinnis RJ, English DR, Giles GG. Effect of physical activity and body size on survival after diagnosis with colorectal cancer. Gut. 2006;55(1):62–67. [PMC free article] [PubMed]
50. Dignam JJ, Polite BN, Yothers G, et al. Body mass index and outcomes in patients who receive adjuvant chemotherapy for colon cancer. J Natl Cancer Inst. 2006;98(22):1647–1654. [PubMed]

Articles from JNCI Journal of the National Cancer Institute are provided here courtesy of Oxford University Press